Recent updates on recombinant human growth hormone outcomes and adverse events

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 1, 2013, Pages 39-43

  Watson, Sara E ^a   Rogol, Alan D ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

idiopathic short stature; outcomes; Prader Willi Syndrome; recombinant human growth hormone; Safety and Appropriateness of Growth Hormone Treatments in Europe

Indexed keywords

HUMAN GROWTH HORMONE;

ADVERSE OUTCOME; BODY HEIGHT; CARBOHYDRATE METABOLISM; COGNITION; DRUG SAFETY; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; HYPOGONADISM; IMPAIRED GLUCOSE TOLERANCE; MORTALITY; OUTCOME ASSESSMENT; PRADER WILLI SYNDROME; REVIEW; SCOLIOSIS; SHORT STATURE; SIDE EFFECT; SLIPPED CAPITAL FEMORAL EPIPHYSIS; SUDDEN DEATH; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; DWARFISM; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; HYPOGONADISM; MALE; PATIENT SELECTION; PRADER-WILLI SYNDROME; PROGNOSIS; QUALITY ASSURANCE, HEALTH CARE; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84871918433     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32835b7ea8     Document Type: Review

References (18)

1. Noto R, Maneatis T, Frane J, et al. Intracranial hypertension in pediatric patients treated with recombinant human growth hormone: data from 25 years of the Genentech National Cooperative Growth Study. JPEM 2011; 24:627-631.
2. Reinehr T, Bechtold-Dalla Pozza S, Bettendorf M, et al. Impact of overweight on effectiveness of treatment with human growth hormone in growth hormone deficient children: analysis of German KIGS data. Exp Clin Endocrinol Diabetes 2011; 119:544-548.
3. Burman P, Ritze'n EM, Lindgren AC. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev 2001; 22: 787-799.
4. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med 2012; 14:10-26.
5. Craig ME, Cowell CT, Larsson P, et al. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol 2006; 65:178-185.
6. Siemensma EP, de Lind van Wijngaarden RF, Otten BJ, et al. Testicular failure in boys with Prader-Willi syndrome: longitudinal studies of reproductive hormones. J Clin Endocrinol Metab 2012; 97:E452-E459.
7. Radicioni AF, Di Giorgio G, Grugni G, et al. Multiple forms of hypogonadism of central, peripheral or combined origin in males with Prader-Willi syndrome. Clin Endocrinol 2012; 76:72-77.
8. Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, et al. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal Study. The J Clin Endocrinol Metab 2012; 97:2307-2314
9. Ranke MB. Towards a consensus on the definition of idiopathic short stature. Horm Res 1996; 45 (Suppl 2):64-66.
10. Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. BMJ. 2011; 342- 349.
11. Ranke MB, Lindberg A. The basis for optimising growth with growth hormone usage in children with idiopathic short stature: analysis of data from KIGS (Pfizer International Growth Study Database). Horm Res Paediatr 2011; 76 (Suppl 3):48-50.
12. Allen DB. Safety of growth hormone treatment of children with idiopathic short stature: the US experience. Horm Res Paediatr 2011; 76 (Suppl 3):45-47.
13. Ambler GR, Fairchild J, Wilkinson DJC. Debate: idiopathic short stature should be treated with growth hormone. J Paediatr Child Health. 2012; [Epub ahead of print].
14. Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 2012; 97:416-425.
15. Savendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab 2012; 97:E213-E217.
16. Bell J, Parker KL, Swinford RD, et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010; 95:167-177.
17. Wilton P, Mattsson AF, Darendeliler F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J Pediatr 2010; 157:265-270.
18. Rosenfeld RG, Cohen P, Robison LL, et al. Long-term surveillance of growth hormone therapy. J Clin Endocrinol Metab 2012; 97:68- 72.